Abstract
One of the main pathological characteristics of Alzheimers disease is the presence in the brain of the patients of an aberrant structure, the paired helical filaments, composed of hyperphosphorylated tau. The level of tau phosphorylation has been correlated with the capacity for tau aggregation. Thus, the mechanism for tau phosphorylation could be important to clarify those pathological features in Alzheimers disease. Tau protein could be modified by different kinases, being GSK3 the one that could modify more sites of that protein. GSK3 activity could be modulate by the presence of metals like magnesium that can be required for the proper function of the kinase, whereas, metals like manganesum or lithium inhibit the activity of the kinase. Many works have been done to study the inhibition of GSK3 by lithium, a specific inhibitor of that kinase. More recently, it has been indicated that sodium tungstate could also inhibit GSK3 through a different mechanism. In this review, we discuss the effect of these two metals, lithium and tungstate, on GSK3 (or tau I kinase) activity.
Keywords: tau kinase, GSK3 inhibition, insulin degrading enzyme (IDE), glycogen synthase (GS), Alzheimer, ’, s disease
Current Alzheimer Research
Title: Inhibition of GSK3 Dependent Tau Phosphorylation by Metals
Volume: 3 Issue: 2
Author(s): Alberto Gomez-Ramos, Jorge Dominguez, Delia Zafra, Helena Corominola, Ramon Gomis, Joan J. Guinovart and Jesus Avila
Affiliation:
Keywords: tau kinase, GSK3 inhibition, insulin degrading enzyme (IDE), glycogen synthase (GS), Alzheimer, ’, s disease
Abstract: One of the main pathological characteristics of Alzheimers disease is the presence in the brain of the patients of an aberrant structure, the paired helical filaments, composed of hyperphosphorylated tau. The level of tau phosphorylation has been correlated with the capacity for tau aggregation. Thus, the mechanism for tau phosphorylation could be important to clarify those pathological features in Alzheimers disease. Tau protein could be modified by different kinases, being GSK3 the one that could modify more sites of that protein. GSK3 activity could be modulate by the presence of metals like magnesium that can be required for the proper function of the kinase, whereas, metals like manganesum or lithium inhibit the activity of the kinase. Many works have been done to study the inhibition of GSK3 by lithium, a specific inhibitor of that kinase. More recently, it has been indicated that sodium tungstate could also inhibit GSK3 through a different mechanism. In this review, we discuss the effect of these two metals, lithium and tungstate, on GSK3 (or tau I kinase) activity.
Export Options
About this article
Cite this article as:
Gomez-Ramos Alberto, Dominguez Jorge, Zafra Delia, Corominola Helena, Gomis Ramon, Guinovart J. Joan and Avila Jesus, Inhibition of GSK3 Dependent Tau Phosphorylation by Metals, Current Alzheimer Research 2006; 3 (2) . https://dx.doi.org/10.2174/156720506776383059
DOI https://dx.doi.org/10.2174/156720506776383059 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Therapy of XDR TB with Thioridazine a Drug Beyond Patent Protection but Eligible for Patent “As New Use”
Recent Patents on Anti-Infective Drug Discovery Bioorganic Compounds Produced by the Fungus Monascus and their Use in Health Sciences and Medicine
Mini-Reviews in Organic Chemistry When Nutraceuticals Reinforce Drugs Side Effects: A Case Report
Current Drug Safety DNA Repair in Premature Aging Disorders and Neurodegeneration
Current Aging Science Editorial [Hot topic: Cognitive Enhancing Drugs: A Blessing for Society? (Joris C. Verster)]
Current Drug Abuse Reviews Neuroprotective Strategies for Parkinsons Disease
Current Neuropharmacology HHT in Childhood: Screening for Special Patients
Current Pharmaceutical Design A Review of the Clinical, Radiological and Biochemical Characteristics and Genetic Causes of High Bone Mass Disorders
Current Drug Targets Autoantibodies Associated with Psychiatric Disorders
Current Neurovascular Research RNA Splicing Manipulation: Strategies to Modify Gene Expression for a Variety of Therapeutic Outcomes
Current Gene Therapy Actions of the Anti-Angiogenic Compound Angiostatin in an Animal Model of Alzheimer’s Disease
Current Alzheimer Research Neuromodulation of Memory Formation and Extinction
Current Neurovascular Research Patent Annotations
Recent Patents on CNS Drug Discovery (Discontinued) The Assessment of Some Metabolic Markers by Combination of Ursolic Acid Supplementation and Resistance Training in Young Older Obese Women
Endocrine, Metabolic & Immune Disorders - Drug Targets Possible Hypoxia Signaling Induced Alteration of Glucose Homeostasis in Rats Exposed to Chronic Intermittent Hypoxia - Role of Antioxidant (Vitamin C) and Ca2+ Channel Blocker (Cilnidipine)
Current Signal Transduction Therapy Editorial [Hot Topic:Active and Passive Aβ-Immunotherapy: Preclinical and Clinical Studies and Future Directions: Part I (Guest Editors: Michael G. Agadjanyan and David H. Cribbs)]
CNS & Neurological Disorders - Drug Targets The Economic Costs for the Control of Cardiovascular Risk: An Overview
Current Pharmaceutical Design The Role of Adipocytokines and Neurohormonal Dysregulation in Metabolic Syndrome
Current Diabetes Reviews Caring for HIV-Infected Patients in the ICU in The Highly Active Antiretroviral Therapy Era
Current HIV Research Inflammatory Cardiovascular Risk Markers in Obstructive Sleep Apnoea Syndrome
Cardiovascular & Hematological Agents in Medicinal Chemistry